Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Genentech, Inc. et al v. Amgen, Inc.
Case Number:
1:17-cv-01471
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
August 03, 2018
PTAB Shoots Down Pfizer's Bid To Review Avastin Patent
The Patent Trial and Appeal Board has turned down Pfizer Inc.'s challenge to a patent covering Genentech Inc.'s blockbuster cancer treatment Avastin, finding the challenger couldn't prove the patent shouldn't have been issued.
-
October 27, 2017
Amgen 'Completely Ignoring' Biosimilar Law, Genentech Says
Amgen Inc. has been "completely ignoring" its information-disclosure obligations under the federal biosimilars law in order to shield its biosimilar of blockbuster cancer drug Avastin, Genentech Inc. claims in a newly unsealed complaint.